Double digit sales growth in albumin and speciality products and influenza vaccine sales have helped CSL announce a net profit after tax of US$692m (A$889m) for the six months ended 31 December 2014. This is up US$47m (A$60m) when compared to the prior comparable period while earnings per share also grew by 10%. “A key
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.